Myovant Sciences Ltd. (NYSE:MYOV) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August10, 2017, Myovant Sciences Ltd. (the “Registrant”) issued a press release announcing its financial results for the three months ended June 30, 2017. A copy of this press release is furnished herewith as Exhibit99.1 to this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. ofForm8-K,the information in this Item 2.02, and Exhibit99.1 hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits.
Press Release of Myovant Sciences Ltd., dated August 10, 2017, “Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30,2017”
Myovant Sciences Ltd. ExhibitEX-99.1 2 a63017ex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30,…To view the full exhibit click
About Myovant Sciences Ltd. (NYSE:MYOV)
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.